HeartBeam (BEAT)
(Delayed Data from NSDQ)
$2.42 USD
-0.17 (-6.56%)
Updated Jun 7, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BEAT 2.42 -0.17(-6.56%)
Will BEAT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BEAT based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BEAT
Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers
Jaguar Health, Altamira Therapeutics,Erasca among healthcare movers
HeartBeam’s Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias
HeartBeam AIMIGo™ Recognized for Digital Health Innovation in 8th Annual MedTech Breakthrough Awards Program
HeartBeam, Inc. 2024 Q1 - Results - Earnings Call Presentation